Strategic Expansion, Technological Milestones, and International Capital Market Presence

Zurich, 25^th of April 2025: Xlife Sciences AG ("Xlife Sciences", SIX: XLS) today published its 2024 Annual Report. The past fiscal year was marked by strategically significant partnerships and technological breakthroughs within its portfolio companies.

«2024 was a successful year for Xlife Sciences in terms of technological progress within our portfolio and strategic exits/transactions being executed on a global scale.» says Oliver R. Baumann, CEO of Xlife Sciences AG. «We not only continued to strengthen our innovation capacity but also laid the foundation for international scalability of our platform through new partnerships and mergers.»

Strategic Partnerships and Technological Advancements
Strengthening international relations was a key element of the corporate strategy in 2024. Important collaborations were established with the Abu Dhabi Department of Health, Thermo Fisher Scientific, and Masdar City. The merger of portfolio company palleos healthcare GmbH with OCT Clinical GmbH marked another milestone in the field of clinical research. Innovative technological developments underlined the strength of the Xlife Sciences portfolio pipeline. Notable examples include:

• x-nuclear diagnostics GmbH reached market maturity for a novel liver diagnostic procedure. This first specific PET tracer for the liver is manufactured in synergy with the portfolio company inflamed pharma GmbH.


• inflamed pharma GmbH has made significant progress in the further development of the JenClutec solubility technology. The platform-based enhancement of drug solubility (in some cases by up to 100,000 times) has been demonstrated for more than 10 classes of active pharmaceutical ingredients. The most advanced and already marketed product is ProcCluster^®, an active ingredient based on procaine.


• VERAXA Biotech AG introduced a groundbreaking technology with its patented BiTAC platform, designed to reduce toxicity and enhance precision and safety in cancer therapy.


• In addition to VERAXA Biotech AG, other portfolio companies secured important patents for their technologies in 2024, including saniva diagnostics GmbH (patents granted in Germany and Japan) as well as x-nuclear diagnostics GmbH (patent granted in South Korea).

Meanwhile, 4D Lifetec AG, a portfolio company, had planned a market entry in the U.S.. Due to a lack of progress in this respect, the company is currently undergoing a strategic realignment. Xlife Sciences is evaluating options for continuation or value realization and the corresponding valuation has been written down to zero.

Proposed Dual Listing Enhances International Capital Market Presence
Xlife Sciences also made the decision to pursue a dual listing on both the Swiss Exchange (SIX) and the London Stock Exchange (LSE). Listing in two major financial centers will increase international visibility and facilitate access to a broader investor base. It will also improve trading liquidity and support a fair market valuation of the company, which aligns with the company's goal of sustainably increasing corporate value and delivering long-term value to its shareholders. Progress is being made towards the LSE dual listing becoming effective in the current financial year.

Key Financial Figures 2024

Outlook for 2025
The focus in 2025 will be on partnering promising technologies. In particular, the transaction with VERAXA, offers the potential for a significant partial exit of the company’s investment. «Our special thanks go to our shareholders, whose trust strengthens our actions.» emphasizes David L. Deck, Chairman of the Board of Directors of Xlife Sciences AG. «We look forward to continuing our shared success story in the coming year.»

The full 2024 Annual Report is now available on the Xlife Sciences AG website:
https://www.xlifesciences.ch/en/news-and-key-figures (Section «Financial Reports»).

The independent valuation report by Cylad Experts for 2024 will be published in the coming days.

Financial calendar

Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, dennis.fink@xlifesciences.ch

Xlife Sciences AG, 
Talacker 35, 
8001 Zurich, 
Switzerland,
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch, 
Commercial Register Zurich CHE-330.279.788 
Stock Exchange: SIX Swiss Exchange